Virtual Library

Start Your Search

Stefan Grau

Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      178P - Feasibility of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for treatment monitoring of brain metastases in lung cancer patients (ID 561)

      12:30 - 13:00  |  Author(s): Stefan Grau

      • Abstract


      Brain metastases (BMs) occur frequently in patients with advanced lung cancer. So far, intracranial efficacy of systemic lung cancer treatment is nearly unpredictable. Contrast-enhanced magnetic resonance imaging (MRI) is considered gold standard for response assessment but lacks potential to discriminate between malignant or active tumor lesions from benign or postinflammatory signal alterations. O-(2- [18F]fluoroethyl)-L-tyrosine (FET)-positron emission tomography (PET) has shown additional diagnostic value over standard MRI in glioma patients. We set out this analysis to determine the feasibility of FET PET in lung cancer patients.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      FET with a mean activity of 200 MBq was produced and FET PET performed 20-40 minutes post injectionem at Research Center Juelich (Forschungszentrum Jülich). Patients with cerebral metastasized lung cancer underwent at least one tomography, and tumor volume and activity were assessed by both standard uptake values (SUVs) or tumor-to-brain ratios. A lesion-brain ratio in the standard uptake value (SUV) of more than 2 was considered pathological.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      From 2015 to 2018, 48 patients received at least one FET PET, whereof 11 patients (22.9%) underwent two scans and one patient three serial FET PETs. All scans could be analyzed for the assessment of tumor activity. The patients did not suffer of adverse events related to the tracer or the procedure. In most cases, FET PET was performed to discriminate between scar tissue and new tumor activity in singular metastases treated stereotactically. In a smaller number of patients, FET PET was used to assess treatment response in systematically treated patients.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      FET PET is feasible in patients with brain metastases of lung cancer and might provide additional information to MRI for treatment decisions in these patients. Validation of the results and the reproducibility is ongoing.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.